GlaxoSmithKline Australia
Administration route: 
Intramuscular injection
Vaccine group: 
Combination vaccines

Registered for primary immunisation in infants aged ≥6 weeks and as a booster in children aged ≤6 years.

DTPa-IPV — diphtheria-tetanus-acellular pertussis-inactivated poliovirus combination vaccine

Each 0.5 mL monodose pre-filled syringe contains:

  • ≥30 IU diphtheria toxoid
  • ≥40 IU tetanus toxoid
  • 25 µg pertussis toxoid
  • 25 µg filamentous haemagglutinin
  • 8 µg pertactin
  • 40 D-antigen units inactivated poliovirus type 1 (Mahoney)
  • 8 D-antigen units inactivated poliovirus type 2 (MEF-1)
  • 32 D-antigen units inactivated poliovirus type 3 (Saukett)

Adsorbed onto aluminium hydroxide hydrate.

Also contains traces of:

  • formaldehyde
  • polysorbate 80
  • polymyxin
  • neomycin

For Product Information and Consumer Medicine Information about Infanrix IPV visit the Therapeutic Goods Administration website- external site.

For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.

Page history

Last updated: 
27 September 2021
Last reviewed: 
27 September 2021


diphtheria-tetanus-acellular pertussis vaccine
inactivated poliomyelitis vaccine
international units